INTRODUCTION: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non-ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. METHODS: Non-ambulatory boys/men with DMD (N = 91; 16.7 ± 4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. RESULTS: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8 ± 22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9-hole peg test, and Jebsen-Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. CONCLUSIONS: Reliable assessment of non-ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use.
INTRODUCTION: Therapeutic trials in Duchenne muscular dystrophy (DMD) often exclude non-ambulatory individuals. Here we establish optimal and reliable assessments in a multicenter trial. METHODS: Non-ambulatory boys/men with DMD (N = 91; 16.7 ± 4.5 years of age) were assessed by trained clinical evaluators. Feasibility (percentage completing task) and reliability [intraclass correlation coefficients (ICCs) between morning and afternoon tests] were measured. RESULTS: Forced vital capacity (FVC), assessed in all subjects, showed a mean of 47.8 ± 22% predicted (ICC 0.98). Brooke Upper Extremity Functional Rating (Brooke) and Egen Klassifikation (EK) scales in 100% of subjects showed ICCs ranging from 0.93 to 0.99. Manual muscle testing, range of motion, 9-hole peg test, and Jebsen-Taylor Hand Function Test (JHFT) demonstrated varied feasibility (99% to 70%), with ICCs ranging from 0.99 to 0.64. We found beneficial effects of different forms of corticosteroids for the Brooke scale, percent predicted FVC, and hand and finger strength. CONCLUSIONS: Reliable assessment of non-ambulatory boys/men with DMD is possible. Clinical trials will have to consider corticosteroid use.
Authors: Sarah E Davis; Linda S Hynan; Christine A Limbers; C Mariam Andersen; Medrith C Greene; James W Varni; Susan T Iannaccone Journal: J Clin Neuromuscul Dis Date: 2010-03
Authors: E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald Journal: Neurology Date: 2010-12-22 Impact factor: 9.910
Authors: Igor Immerman; Daniel T Alfonso; Lorna E Ramos; Leslie A Grossman; Israel Alfonso; Patricia Ditaranto; John A I Grossman Journal: Dev Med Child Neurol Date: 2011-12-01 Impact factor: 5.449
Authors: Elena S Mazzone; Gessica Vasco; Concetta Palermo; Flaviana Bianco; Carmen Galluccio; Valeria Ricotti; Antonella D Castronovo; Maria Sole D I Mauro; Marika Pane; Anna Mayhew; Eugenio Mercuri Journal: Dev Med Child Neurol Date: 2012-06-19 Impact factor: 5.449
Authors: Kevin M Flanigan; Ermelinda Ceco; Kay-Marie Lamar; Yuuki Kaminoh; Diane M Dunn; Jerry R Mendell; Wendy M King; Alan Pestronk; Julaine M Florence; Katherine D Mathews; Richard S Finkel; Kathryn J Swoboda; Eduard Gappmaier; Michael T Howard; John W Day; Craig McDonald; Elizabeth M McNally; Robert B Weiss Journal: Ann Neurol Date: 2013-02-20 Impact factor: 10.422
Authors: Jonathan H Soslow; Meng Xu; James C Slaughter; Kimberly Crum; Joshua D Chew; W Bryan Burnette; Yan Ru Su; Kelsey Tomasek; David A Parra; Larry W Markham Journal: J Card Fail Date: 2019-02-11 Impact factor: 5.712
Authors: David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber Journal: Lancet Neurol Date: 2018-02-03 Impact factor: 44.182
Authors: Saskia L S Houwen-van Opstal; Lotte Heutinck; Merel Jansen; Yvonne D Krom; Edith H C Cup; Jos G M Hendriksen; Michel A A P Willemsen; Jan J G M Verschuuren; Erik H Niks; Imelda J M de Groot Journal: Muscle Nerve Date: 2021-09-09 Impact factor: 3.852
Authors: Greta Culicchia; Marta Nobilia; Marilyn Asturi; Valter Santilli; Marco Paoloni; Rita De Santis; Giovanni Galeoto Journal: Rehabil Res Pract Date: 2016-07-18